Abstract: The invention relates to a thermolabile liposome with controlled release temperature for the liposome content, which is essentially formed by at least one phosphatidyl choline with a main transition temperature ranging from 0 to 80° C. and 2 to 15 percent by weight of phosphatidyl oligoglycerin.

Abstract: The invention relates to a thermolabile liposome with a controlled release temperature for the liposome content, in particular a liposome which is stable at 37° C. in serum and with a controlled release temperature of between 40 and 80° C.

Abstract: The invention concerns a pharmaceutical preparation which improves penetration of active substances through the tissue membrane or barrier of the target organ.

Abstract: The invention concerns a pharmaceutical preparation which improves penetration of active substances through the tissue membrane or barrier of the target organ.

Abstract: The invention relates to a thermolabile liposome with a controlled release temperature for the liposome content, in particular a liposome which is stable at 37° C. in serum and with a controlled release temperature of between 40 and 80° C.

Abstract: The present invention relates to novel phosphoric triesters which comprise apolar lipid structures.

Abstract: The invention concerns a pharmaceutical preparation which improves penetration of active substances through the tissue membrane or barrier of the target organ.

Abstract: The invention relates to a thermolabile liposome with controlled release temperature for the liposome content, which is essentially formed by at least one phosphatidyl choline with a main transition temperature ranging from 0 to 80° C. and 2 to 15 percent by weight of phosphatidyl oligoglycerin.

Abstract: The invention relates to drug formulations for stimulating leukopoiesis and for treating tumor diseases and protozoal diseases, and acariasis and diseases caused by arthropods, which formulations are characterized in that they comprise an effective mixture composed of a) at least one phospholipid compound of the formula I: 1

Abstract: The object of the invention is to provide a medicament which is suitable for the treatment of tumors, such as via topical administration.

Abstract: The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I 1

Abstract: The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I ##STR1## in which R.sup.1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R.sup.2, R.sup.3 and R.sup.4 denote independently of one another hydrogen, a C.sub.1 -C.sub.5 alkys group, a C.sub.3 -C.sub.6 cycloalkyl group or a C.sub.1 -C.sub.5 hydroxyalkyl group whereby two of the residues R.sup.2, R.sup.3 and R.sup.4 can together form a C.sub.2 -C.sub.5 alkylene group which, if desired, can be substituted with an --O--, --S-- or NR.sup.5 group, in which R.sup.5 is hydrogen, a C.sub.1 -C.sub.5 alkyl group, a C.sub.3 -C.sub.6 cycloalkyl group or a C.sub.1 -C.sub.5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.

Abstract: Cytotoxic therapeutic compositions contain as active ingredients compounds of the formulaR--Y--PO.sup..theta..sub.2 --X--R.sub.1wherein R is a saturated or unsaturated hydrocarbon radical of 12 to 14 carbon atoms which may also be halogen-substituted, X is oxygen, --NH-- or --NR.sub.2 --, Y is oxygen or --NH-- and R.sub.1 has diverse meanings or physiologically acceptable salts thereof.

Abstract: The present invention concerns liposomes with a negative excess charge and pharmaceutical compositions produced therefrom. The liposomes contain 30 to 50 mol % cholesterol, 49 to 56 mol % phospholipids and 1 to 14 mol % of one or several compounds of the general formula I ##STR1## or salts thereof in relation to the total lipid components of the liposomes, in which R.sup.1 and R.sup.2 are the same or different and represent hydrogen, C.sub.1 -C.sub.4 alkyl groups or saturated or unsaturated C.sub.8 -C.sub.24 acyl groups which are unbranched or branched or/and unsubstituted or substituted, provided that at least one of the residues R.sup.1 and R.sup.2 is an acyl group as defined above. A process for the production of the liposomes in accordance with the invention is also provided.

Abstract: The present invention provides compounds of the formula: ##STR1## wherein R is a erucyl, brassidyl or nervonyl radical, R.sup.1, R.sup.2 and R.sup.3 are defined in the specification, A is a valency bond or a radical as defined in the specification, and X is an oxygen atom when A is a valency bond or is an oxygen or sulphur atom when A is another radical.The present invention also provides a process for the preparation of the compounds of general formula (I) and pharmaceutical compositions containing them which can be used for the treatment of protozoal and fungal diseases, auto-immune diseases and bone marrow damage.

Abstract: The use of alkylphosphoric acid compounds of Formula IR--Y--PO.sub.2.sup..crclbar. --X--R.sub.1 Iwhere in Formula IR represents a saturated or unsaturated hydrocarbon radical with 12 to 24 carbon atoms or where R represents the group--CH.sub.2 --CHR.sub.3 --CH.sub.2 --Z--R.sub.4 and R.sub.3 is a C.sub.1 -C.sub.6 -alkoxy group or a C.sub.1 -C.sub.6 -alkoxymethyl group,Z represents oxygen or sulphur and R.sub.4 represents a C.sub.1 -C.sub.24 -alkyl radical,X is an oxygen atom, NH or NR.sub.2 and Y is an oxygen atom or NH, R.sub.1 is a C.sub.1 -C.sub.8 -alkyl group, or where R.sub.1 represents a C.sub.2 -C.sub.8 -alkyl group which is unsaturated and/or substituted by halogen, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino, tri-C.sub.1 -C.sub.6 -alkylamino, hydroxy, carboxy, C.sub.3 -C.sub.8 -cycloalkyl or phenyl for the preparation of a pharmaceutical composition for combating psoriasis disorders.

Abstract: A composition useful as a medicament with improved penetration of cell membranes comprising an active material and a compound of general formula: ##STR1## wherein either residue R.sub.1 or R.sub.2 is an alkyl, alkylene, alkynyl or alkoxy group of 3-7 carbon atoms, and the other residue is a hydrogen atom, together with pharmaceutical additives and dilution agents.

Abstract: The invention relates to compositions containing hexadecylphosphocholine the use of these in treating various cancers.

Abstract: The invention relates to pharmaceutical compositions containing synthetic, substantially pure phosphatidyl serine and phosphatidyl choline and a substance or a mixture of substances having biological activity. The invention also relates to mixtures comprising synthetic, substantially pure phosphatidyl serine and phosphatidyl choline, and also to processes for the manufacture of the pharmaecutical compositions, and the use thereof.

Abstract: Cytotoxically-effective medicaments containing hexadecylphosphocholine as active material.